Clear Street’s Aspire Biopharma ASBP Stock Holding History

Clear Street’s Portfolio ASBP Stock Details ASBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-13	Closed	-$183K	–	634
2024 Q4	$183K	Buy	13 +7	+117%	+$98.9K	﹤0.01%	99
2024 Q3	$93.9K	Hold	6	–	–	﹤0.01%	153
2024 Q2	$81.7K	Sell	6 -36	-86%	-$490K	﹤0.01%	185
2024 Q1	$559K	Buy	+42	New	+$552K	0.01%	71
2023 Q3	–	Sell	-41	Closed	-$516K	–	1327
2023 Q2	$516K	Buy	+41	New	+$515K	0.01%	266
2023 Q1	–	Hold	0	–	–	–	775

Other funds holding ASBP

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Crewe Advisors Salt Lake City, Utah $1.17B AUM 29.21% 1-Year Est. Return

HCI

Harraden Circle Investments New York $499M AUM 24.03% 1-Year Est. Return

OAS

Optivise Advisory Services Franklin, Tennessee $197M AUM 26.07% 1-Year Est. Return

Procyon Advisors Shelton, Connecticut $2.32B AUM 26.81% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

PTP

Platform Technology Partners New York $519M AUM 20% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Clear Street's ASBP Position: Q1 2025 in Review

Clear Street sold out of Aspire Biopharma (ASBP) in Q1 2025, closing a stake of 13 shares — an estimated $183K sold.

Clear Street first reported a position in ASBP in Q2 2023 and held it in 5 quarters. The position peaked at $559K in Q1 2024. 13 funds tracked by Wall St. Rank hold ASBP as of Q1 2025.

Clear Street reported no remaining Aspire Biopharma position as of Q1 2025 after selling out during the quarter.
Clear Street sold 13 Aspire Biopharma shares in Q1 2025, an estimated $183K.
Clear Street first reported a position in Aspire Biopharma in Q2 2023 and held it in 5 quarters.
Clear Street's Aspire Biopharma position peaked at $559K in Q1 2024.
13 funds tracked by Wall St. Rank held Aspire Biopharma as of Q1 2025.

Based on Clear Street's 13F filing for Q1 2025, filed 15 May 2025.